Immervision Develops Advanced Vision System for IONODES New PERCEPT Body Camera
Immervision, the world’s leading developer of advanced vision systems combining optics, image processing, and sensor fusion technology, today announced its ultra-wide lenses will be integrated into IONODES’ PERCEPT body camera. This collaboration will give businesses and the general public greater peace of mind, by providing physical security workers with a body camera that can effectively capture in real-time any potential security threats or issues in high resolution and never miss a detail through a Panomorph lens with 180° field of view.
“In the physical security industry, the challenge that most companies face with body worn cameras is that the video fails to effectively capture what’s occurring due to narrow field-of-view and poor image resolution,” said Eric Tasso, President at IONODES. “By selecting Immervision technology and their team of experts, we are providing security, industrial and commercial organizations with the highest-quality wearable cameras to improve safety, enhance security, optimize business processes and provide transparency."
IONODES’ body-worn IoT device is the first of a series of products that combines Immervision’s ultra-wide-angle lens, image processing and sensor technology with IONODES 4K camera, and connects to Wi-Fi, Bluetooth and LTE. IONODES’ device integrates seamlessly with a GPS receiver and 9-axis motion sensor, allowing users to closely follow the field of view in real-time, to stabilize the image and provide location tracking to users, whether for security, prevention, monitoring or entertainment applications
“Over the last 20 years, Immervision has focused on cultivating and perfecting its expertise in advanced vision systems, giving devices in industries such as physical security the ability to truly perceive the world around them,” said Pascale Nini, President and CEO at Immervision. “Immervision and IONODES are deeply committed to offering the best vision systems in the market for security and surveillance, and we look forward to continuing to make more innovative strides in developing high-quality wearable camera devices and AI-based vision systems.”
About Immervision
With over 20 years of innovation, Immervision creates solutions to see beyond human vision. To enable a machine to exceed human vision and unlock the full potential of AI, we develop advanced vision systems combining optics, image processing, and sensor fusion technology. Our Deep Seeing Technology enables hardware and software manufacturers to equip smart devices with the best vision possible for any industry including transportation, security, defense, computing, robotics, and more. www.immervision.com
About IONODES
IONODES is focused on pushing the boundaries of video technology, developing the latest in IP video storage, management and display solutions. Its experience in IP video and strong partnerships with industry leaders deliver innovative products designed to enhance people’s lifestyle while ensuring their safety and security.
IONODES designs, develops, and manufactures IP-based video solutions optimized for use in video surveillance. Its products include smart IP video appliances, such as body worn cameras, video encoders, video wall appliances, recording servers and workstations. The company offers its products through distributors, resellers, and representatives worldwide.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123006095/en/
Contact information
Paige McEachren
paige.mceachren@immervision.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom